AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance
Fiscal Year 2024 Second Quarter Highlights Net sales of $79.1 million increased 2.7% on a pro-forma basis compared to the...
Clinical Trial
Metrodora Institute Announces New Chief Scientific Officer
Rohit Gupta, a Nationally Recognized Scientist, Biobank and Data Expert, is Named as Metrodora Institute's New Chief Scientific Officer and...
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
Head-to-head comparison with licensed bivalent mRNA-based comparator vaccine confirms competitive immune responses at lower doses and favorable tolerability profileMonovalent mRNA...
Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones
- EU Clinical Trials authorized for Phase 1b/2a SPOTLIGHT and BEACON studies of briquilimab in CIndU and CSU, respectively -...
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
If approved, DFD-29 has potential to be best-in-class and the only oral medication to address both inflammatory lesions and erythema...
Axial Therapeutics to Present at Upcoming Conferences
WOBURN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biotechnology company dedicated to the development of gut-targeted,...
Spero Therapeutics Provides Corporate Update and 2024 Outlook
In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients...
Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660, Dolasynthen B7-H4 ADC; expect to...
Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer
CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a...
Compass Therapeutics Provides Corporate Update
We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x...
Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement
Three-year research collaboration will investigate the development of scalable, commercial delivery models for COMP360 psilocybin treatment, if FDA-approvedLONDON, Jan. 05,...
Fractyl Health Announces Nomination of RJVA-001 as First Clinical Candidate in Its Rejuva® GLP-1 Gene Therapy Platform
RJVA-001 is the first GLP-1 pancreatic gene therapy (GLP1 PGTx) candidate to be nominated by the Company and is designed...
Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
There are approximately 3-4 million diagnoses of basal cell carcinomas in the U.S. each year, with a high unmet need...
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation Increasing commercial access to...
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
Partnership focused on utilizing Axiomer™ to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett syndromeCollaboration expands ProQR’s...
Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities
RAPIDe-3, a global Phase 3 clinical study of deucrictibant for the on-demand treatment of HAE, to initiate within 1H24Results of...
Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patients with Metastatic Castration-Resistant Prostate Cancer
ORION CORPORATION PRESS RELEASE05 JANUARY 2023 at 13:45 EET Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684...
Bionomics to Present at Biotech Showcase™ 2024
The Company will provide an update on its leading asset BNC210 and their partnership strategyADELAIDE, Australia and CAMBRIDGE, Mass., Jan....
Addex to Present at Biotech Showcase™ 2024
CEO to provide update on allosteric modulator pipeline clinical and preclinical development Geneva, Switzerland, January 5, 2024 - Addex Therapeutics...
Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on Three Key KRAS Mutations Identified in Drug Resistant Lung, Colon and Pancreatic Cancers
GRAD1405 uses Gradalis’ breakthrough gene silencing bi-shRNAi technology to specifically reduce the expression of certain mutated KRAS genesExisting therapies have...